Let's Talk About Risk: FDA Plans Meeting On Postmarket Risk Management
This article was originally published in The Silver Sheet
Executive Summary
Online-Only Content >>> FDA will hold an interactive workshop on April 21 to discuss the "clinical considerations of risk in the postmarket environment." The meeting will build on a process launched last fall when representatives from industry and FDA met to establish draft principles for managing unanticipated risks for marketed devices.
You may also be interested in...
Industry, FDA Coming Together On Risk Management For Marketed Devices
Online-Only Content >>> Representatives from the device industry and FDA are trying to establish common ground for how to assess and manage risk of potential safety or compliance issues that crop up for marketed devices.
Speaking Of Medtech, Ep. 10: FDA’s TAP Pilot
In this FINAL EPISODE of Speaking Of Medtech: The US FDA got something it desperately wanted in its latest user-fee package with industry: a Total Product Lifecycle Advisory Program pilot, or TAP. The agency says TAP will allow for earlier and more frequent engagement with developers – but is it needed?
Thumbs Up: FDA Authorizes Weight Loss Suturing Systems From Apollo Endosurgery
People with obesity now have new tools to help them lose weight, thanks to the US agency’s de novo authorization.